Phase II trial of nivolumab following radiation therapy to bone metastases in patients with non-small cell lung cancer

Phase 2

• Conditions: non-small cell lung cancer with bone metastasis

• Registration Number: JPRN-UMIN000025878
• Lead Sponsor: niversity of Tsukuba Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-02-01
• Study Completion: 2021-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1) Positive for epidermal grow factor receptor activating mutation or ALK re-arrangement 2) Active malignancies within 2 years 3) Active infection requiring intravenous systemic therapy or hospital admission 4) A history of interstitial lung disease 5) A history of active, known autoimmune disease. 6) Requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications. 7) Active CNS metastasis 8) Carcinomatous meningitis 9) Positive for HBs antigen or HBV-DNA positive 10) Positive for HCV antibody 11) Pregnant or breast-feeding women 12) Any other patients whom the doctor judged to be unsuitable for this trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified